Masimo (MASI) Competitors

Masimo (NASDAQ:MASI) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.

Does the media prefer MASI or DXCM?

In the previous week, DexCom had 20 more articles in the media than Masimo. MarketBeat recorded 29 mentions for DexCom and 9 mentions for Masimo. DexCom's average media sentiment score of 1.44 beat Masimo's score of 1.37 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Masimo	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	25 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is MASI or DXCM more profitable?

DexCom has a net margin of 14.29% compared to Masimo's net margin of 3.85%. DexCom's return on equity of 30.14% beat Masimo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	3.85%	14.98%	6.95%
DexCom	14.29%	30.14%	10.11%

Which has better earnings & valuation, MASI or DXCM?

DexCom has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$2.13B	3.98	$81.50M	-$9.17	-17.03
DexCom	$4.15B	8.26	$576.20M	$1.34	65.18

Does the MarketBeat Community favor MASI or DXCM?

DexCom received 517 more outperform votes than Masimo when rated by MarketBeat users. Likewise, 71.79% of users gave DexCom an outperform vote while only 63.85% of users gave Masimo an outperform vote.

Company	Underperform	Outperform
Masimo	Outperform Votes 468 63.85%	Underperform Votes 265 36.15%
DexCom	Outperform Votes 985 71.79%	Underperform Votes 387 28.21%

Do analysts rate MASI or DXCM?

Masimo currently has a consensus target price of $191.60, indicating a potential upside of 22.69%. DexCom has a consensus target price of $98.11, indicating a potential upside of 12.33%. Given Masimo's higher probable upside, equities research analysts clearly believe Masimo is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
DexCom	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.95

Which has more risk and volatility, MASI or DXCM?

Masimo has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.

Do institutionals and insiders believe in MASI or DXCM?

86.0% of Masimo shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 9.7% of Masimo shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

DexCom beats Masimo on 16 of the 19 factors compared between the two stocks.